FDA approves Roche’s Tecentriq + lurbinectedin as first-line maintenance therapy for lung cancer
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
Takeda will seek an external partner to leverage its cell therapy platform technologies
The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology
The Hub & Spoke model is designed to extend advanced medical care to a wider community
The platform integrates artificial intelligence into a unified environment that supports optical, microCT, ultrasound, and other imaging modalities
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
Subscribe To Our Newsletter & Stay Updated